Filter by content type
Filter by year
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 13, 2020 - … and loss of brain metabolic activity. Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung C linical T rial . The recently completed CLASSICAL-Lung study evaluated pepinemab in combination with …
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
October 26, 2020 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. The company is also … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. The company is also … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. The company is also …
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
September 22, 2020 - … with avelumab checkpoint inhibitor in Non-Small Cell Lung Cancer . A new collaboration with Merck to test the … with currently active clinical trials in Non-Small Cell Lung Cancer , Huntington's and Alzheimer's disease and a … with avelumab checkpoint inhibitor in Non-Small Cell Lung Cancer . A new collaboration with Merck to test the …
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 14, 2020 - … will be released by early October 2020 . Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung clinical trial . The CLASSICAL-Lung study is evaluating pepinemab in combination …
Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease
July 7, 2020 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease and new trials pending … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease and new trials pending … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease and new trials pending …
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 - … Earnings Approaching key topline data in non-small cell lung cancer and Huntington's disease Advancing plans to … Accomplishments: Presented updated interim data from the CLASSICAL-Lung Phase 1b/2 study of the company's lead product … . Pepinemab Clinical Updates: Non-Small Cell Lung Cancer - CLASSICAL-Lung Clinical Trial . The company's ongoing …
Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
May 13, 2020 - … Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … Annual Meeting Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
June 9, 2020 - … clinical trials in Huntington's disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . … clinical trials in Huntington's disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . … clinical trials in Huntington's disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . …
Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
April 27, 2020 - … Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … (AACR) Virtual Annual Meeting Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs
March 31, 2020 - … Key trials in Huntington's disease and non-small cell lung cancer are near completion; company working with trial … and will provide further updates as warranted. CLASSICAL-Lung. The CLASSICAL-Lung study is evaluating pepinemab in combination …